Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trinity Biotech ( (TRIB) ) has provided an update.
On February 19, 2026, Trinity Biotech received a notice from Nasdaq that it no longer meets the Nasdaq Global Select Market requirement to maintain a minimum $15 million market value of publicly held shares over 30 consecutive business days. The company’s American Depositary Shares will continue trading under the TRIB symbol for now, so there is no immediate impact on trading or shareholder ability to buy and sell the stock.
Trinity Biotech has 180 calendar days, until August 18, 2026, to regain compliance by lifting its market value of publicly held shares above $15 million for at least 10 consecutive business days. If it fails to do so, the company could seek a transfer to the Nasdaq Capital Market or face potential delisting and an appeal process, introducing uncertainty for investors and highlighting pressure on the firm’s market valuation despite its ongoing diagnostics and biosensor initiatives.
The most recent analyst rating on (TRIB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. It develops, acquires, manufactures and markets diagnostic systems, such as reagents and instruments for point-of-care and clinical laboratories, and has recently expanded into continuous glucose monitoring via the acquisition of Waveform Technologies’ biosensor assets.
Average Trading Volume: 3,302,868
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.14M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.